Dr. Reddy's Laboratories Announces the Launch of Paricalcitol Injection in the U.S. Market
Tuesday, September 20, 2016
Dr. Reddy’s Laboratories Ltd. announced that it has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar® (paricalcitol) Injection in the United States market approved by the U.S. Food & Drug Administration (USFDA).
The Zemplar® brand and generic had U.S. sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.
Dr. Reddy’s Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.
Zemplar® is a registered trademark of ABBVIE Inc.
*IMS National Sales Perspective: Retail and Non-Retail MAT July 2016
Source : finance.yahoo.com
